Drug Trial Radar · NCT07619833
To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
510
Planned (sponsor's estimate)
Start
Jun 2026
Primary completion
Nov 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.Industry
- Sponsor type
- Industry
- First posted
- Jun 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the efficacy and safety of initial combination therapy with DWP16001 and DWC202518 compared to DWP16001 monotherapy and DWC202518 monotherapy in patients with Type 2 Diabetes Mellitus
Conditions
- T2DM (Type 2 Diabetes Mellitus)
Interventions
DWP16001Drug
DWP16001 0.3mg, Tablets, Orally, Once daily
DWC202518Drug
DWC202518, Tablets, Orally, Once daily
Placebo of DWP16001Drug
DWP16001 placebo-matching tablets
Placebo of DWC202518Drug
DWC202518 placebo-matching tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1c at Week 24 from Baseline after RandomizationTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kangbuk Samsung Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.